Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EYA2 | O00167 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248524 | 0.93 | TDP1 (0.34) | EYA2APPACETDP1 | |
| SCHEMBL20445486 | 0.87 | TDP1 (0.39) | EYA2APPACETDP1 | |
| SCHEMBL22227373 | 0.83 | — | — | |
| SCHEMBL20438445 | 0.79 | TDP1 (0.46) | EYA2APPACETDP1 | |
| SCHEMBL15982284 | 0.79 | TDP1 (0.56) | EYA2APPACETDP1 | |
| SCHEMBL24403604 | 0.77 | TDP1 (0.34) | EYA2APPACETDP1 | |
| SCHEMBL19543431 | 0.77 | TDP1 (0.48) | EYA2APPACETDP1 | |
| SCHEMBL18879446 | 0.76 | — | — | |
| SCHEMBL22692682 | 0.75 | BLM (0.31) | — | |
| SCHEMBL22692686 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277401-A1 | Compositions and Methods for Modulating PKK Expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-9994855-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9932581-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277401-A1 | Compositions and Methods for Modulating PKK Expression | GCKR, PKM, PKLR | EYA2 1087/4885APP 1255/4885ACE 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.